siRNA and Diabetes

I'll be keeping my eyes on this and post updates.

Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic M
Clinical Program Leverages Quark's RNAi Technology FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics,...

Improving 27mer DsiRNA Performance

The DsiRNA story marches forward with yet another important publication. We will give you an opportunity to upload the fulltext article at the end of this posting.

Dr. Mark Behlke, Dr John Rossi and team have been gaining deeper understanding of the Mechanism of Dicer-substrate small-interfering RNA (DsiRNA) processing. This understanding is leading to better and better designs of the RNA duplexes. These designs or chemical modifications are necessary steps in the drug design and development process.

This publication looks at design from the perspective of:

Nuclease Stability
Pharmacokinectics
immune response

I believe this is an important publication for researchers wanting to better understand:

The mechanisms behind successful delivery of DsiRNA for gene expression studies.
Variations in potency.

upload article: oligo-18-p187-2008-collingwood-dsirna-modifications1

Coming Soon

Agenda Topics:
Target Discovery and Validation
Transfection
siRNA Therapeutics
in vivo RNAi-recent in vivo RNAi Pubs
Bioinformatics of small RNAs
siRNA library screens
microRNAs in
Disease Biology:

Stem Cell Biology

Diagnostics

Virology

Biogenesis

Development